Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

被引：0
|
作者：
Park, W. [1 ]
Lopes, G. [1 ]
Kwon, D. [2 ]
Florou, V. [1 ]
Chae, Y. K. [3 ]
Warsch, J. [4 ]
Ishkanian, A. [5 ]
Jahanzeb, M. [6 ]
Mudad, R. [1 ]
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA
[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA
[5] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA
[6] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Tumor mutation burden; biomarker; Nivolumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.07-025
引用
收藏
页码：S2004 / S2005
页数：2
相关论文
共 50 条
  • [31] Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
    Tanaka, Kentaro
    Chamoto, Kenji
    Saeki, Sho
    Hatae, Ryusuke
    Ikematsu, Yuki
    Sakai, Kazuko
    Ando, Nobuhisa
    Sonomura, Kazuhiro
    Kojima, Shinsuke
    Taketsuna, Masanori
    Kim, Young Hak
    Yoshida, Hironori
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Hirano, Tomoko
    Matsuda, Fumihiko
    Hirai, Toyohiro
    Nishio, Kazuto
    Sakagami, Takuro
    Fukushima, Masanori
    Nakanishi, Yoichi
    Honjo, Tasuku
    Okamoto, Isamu
    SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (675)
  • [32] Efficacy and Tolerability of Nivolumab in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Yamane, K.
    Takeda, K.
    Yanai, M.
    Tanaka, N.
    Izumi, H.
    Sakamoto, T.
    Yamaguchi, K.
    Yamasaki, A.
    Igishi, T.
    Eiji, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1918 - S1918
  • [33] Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout
    Antoniu, Sabina
    Ulmeanu, Ruxandra
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (10)
  • [34] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
    Keating, Gillian M.
    DRUGS, 2016, 76 (09) : 969 - 978
  • [35] Outcomes of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) in A Regional Australian Population
    Kasherman, Lawrence
    Brungs, Daniel
    Bell, Graeme
    Glasgow, Amanda L.
    Tafreshi, Ali
    Clingan, Philip
    Aghmesheh, Morteza
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 145 - 146
  • [36] Tumor Mutational Burden in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy: Outcomes in a Multiethnic Cohort
    Munoz-Arcos, L.
    D'Aiello, A.
    Herbert, J.
    Cheng, H.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S408 - S409
  • [37] Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
    Keating, Gillian M.
    DRUGS, 2015, 75 (16) : 1925 - 1934
  • [38] Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2016, 76 : 969 - 978
  • [39] Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2015, 75 : 1925 - 1934
  • [40] The safety of nivolumab for the treatment of advanced non-small cell lung cancer
    Metro, Giulio
    Ricciuti, Biagio
    Brambilla, Marta
    Baglivo, Sara
    Soli, Irene
    Minenza, Elisa
    Leonardi, Giulia Costanza
    D'arpino, Alessandro
    Colabrese, Daniela
    Tazza, Marco
    Zicari, Daniela
    Minotti, Vincenzo
    Chiari, Rita
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (01) : 101 - 109
12345